Article

## **Total Synthesis of the Eight Diastereomers of the Syn-Anti-Syn** Phytoprostanes F<sub>1</sub> Types I and II

Siham El Fangour, Alexandre Guy, Valérie Despres, Jean-Pierre Vidal, Jean-Claude Rossi, and Thierry Durand\*

UMR CNRS 5074, Université Montpellier I, Faculté de Pharmacie, 3e Etage-15, Avenue Charles Flahault, *F*-34093 Montpellier Cedex 05, France

#### thierry.durand@univ-montp1.fr

Received November 7, 2003

Syntheses of the eight enantiomerically pure diastereomers of the syn-anti-syn phytoprostanes  $F_1$ types I and II are described starting from D- and L-glucose. Key steps include Wittig coupling, Horner Wadsworth Emmons (HWE) reactions, and enantioselective reduction of  $\alpha,\beta$ -unsaturated ketones.

#### Introduction

Isoprostanes (IsoPs) represent a new family of biomarkers for oxidative stress generated from peroxidation of polyunsaturated fatty acids via a free-radical-catalyzed mechanism.<sup>1,2</sup> Higher plants generally do not synthesize the arachidonate precursor required for isoPs formation, but rather utilize  $\alpha$ -linolenic acid for the formation of isoprostane F<sub>2</sub>-like compounds which have been termed phytoprostanes F<sub>1</sub> (PPF<sub>1</sub>).<sup>3</sup> Jasmonates are established plant signaling compounds inducing defense responses.<sup>4</sup> Preliminary data indicate that phytoprostanes also induce phytoalexins in a variety of plant species, suggesting a possible function of phytoprostanes as mediators of plant defense reactions in response to oxidative stress.<sup>5,6</sup> Since we were interested in assessing the physiological activities of each of the phytoprostanes  $F_1$  types I and II, we found it more attractive to obtain sufficient quantities by chemical synthesis.

In 2003, we published a note describing the syntheses of *ent*-PPF<sub>1</sub> type I **1** and its 16-epimer **2**.<sup>7</sup> We now report the syntheses of all eight diastereomers of the syn-antisyn PPF<sub>1</sub> types I and II starting from cyclopentane precursors 3 and 3', obtained from D- and L-glucose (Scheme 1).

#### **Results and Discussion**

The Phytoprostanes F<sub>1</sub> types I and II were identified from autoxidation of  $\alpha$ -linolenic acid by Mueller.<sup>3</sup> To confirm the stereochemistry of the eight enantiomerically pure diastereomers of phytoprostanes F<sub>1</sub> types I and II, and also to screen the physiological activity of these phytoprostanes, we have developed a general and flexible strategy from our common intermediate syn-anti-syn cyclopentane precursors 3 and 3' (Scheme 1).

Synthesis of *ent*-Phytoprostane F<sub>1</sub> Type I 1 and **2 from D-Glucose.** The syntheses of *ent*-PPF<sub>1</sub> type I **1** and its 16(S) epimer **2** from the cyclopentane percursor **3** is shown in Schemes 2-4 and was published as a note.<sup>7</sup> The first 9 steps leading to cyclopentane alkoxyester 3 were achieved in 27% overall yield by using our iodo pathway.8

The phosphorus synthon 7 was selected for the introduction of the upper chain of the PPF<sub>1</sub> type I, and was prepared by using the procedure outlined in Scheme 2.

The first step is the opening of the  $\epsilon$ -caprolactone under acidic conditions leading to the corresponding hydroxy methyl ester 5. Subsequent halogenation gave iodo ester 6, which was transformed into the phophonium salt 7 in 98% yield in the presence of PPh3 and a catalytic amount of K<sub>2</sub>CO<sub>3</sub>.

The introduction of the upper chain (Scheme 3) was achieved by using the above phosphonium salt 7, which

<sup>\*</sup> Address correspondence to this author. Phone: 33-4-67-54-86-23. Fax: 33-4-67-54-86-25.

<sup>(1) (</sup>a) Morrow, J. D.; Hill, K. E.; Burk, R. F.; Nammour, T. M.; Badr, K. F.; Roberts, L. J., II Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 9383- Bischem. Biophys. Res. Commun. 1998, 242, 338–344. (c) Roberts, L. J., II; Montine, T. J.; Markesbery, W. R.; Tapper A. R.; Hardy, P.; Chemtob, S.; Dettbarn, W. D.; Morrow, J. D. J. Biol. Chem. 1998, 273, 13605–13612. (d) Nourooz-Zadeh, J.; Liu, E. H. C.; Yhlen, B.; Änggard, E. E.; Halliwell, B. J. Neurochem. 1999, 72, 734-740.

<sup>(2) (</sup>a) Roberts, L. J., II; Morrow J. D. Free Radical Biol. Med. 2000, 28, 505–513. (b) Cracowski, J. L.; Durand, T.; Bessard, G. Trends Pharmacol. Sci. 2002, 23, 360–366.

<sup>(3)</sup> Imbusch, R.; Mueller, M. J. Plant Physiol. 2000, 124, 1293-12303.


<sup>(4)</sup> Stintzi, A.; Weber, H.; Reymond, P.; Browse, J.; Farmer, E. E. *Proc. Natl. Acad. Sci. U.S.A.* **2001**, *98*, 12837–12842.


<sup>(5)</sup> Imbusch, R.; Mueller, M. J. Free Radical Biol. Med. 2000, 28, 720 - 726.

<sup>(6)</sup> Thoma, I.; Loeffler, C.; Sinha, A. K.; Gupta, M.; Krischke, M.; Steffan, B.; Roitsch, T.; Mueller, M. J. *Plant J.* **2003**, *34* (3), 363–375.


<sup>(7)</sup> El Fangour, S.; Guy, A.; Vidal, J.-P.; Rossi, J.-C.; Durand, T. *Tetrahedron Lett.* 2003, 44, 2105–2108.
(8) Durand, T.; Guy, A.; Henry, O.; Vidal, J. P.; Rossi, J. C. *Eur. J.* Org. Cham. 2001, 4, 200, 2010, and article.

Org. Chem. 2001, 4, 809-819 and references therein.





SCHEME 2. Synthesis of Phosphonium Salt 7<sup>a</sup>



<sup>a</sup> Reagents and conditions: (a) MeOH, H<sub>2</sub>SO<sub>4</sub>, rt, 30 min, 94%. (b) I<sub>2</sub>, PPh<sub>3</sub>, imidazole,  $CH_2Cl_2 - 10$  °C, 2 h, 61%. (c) PPh<sub>3</sub>,  $CH_3CN$ , 1% K<sub>2</sub>CO<sub>3</sub>, 18 h, 98%.

reacts with the aldehyde **8** to afford the pure (Z)-enic ester **9** in 70% yield. No trace of trans compound could be detected by  ${}^{13}$ C and  ${}^{1}$ H NMR analyses.

The following reduction of the cis double bond of **9** under hydrogen atmosphere gave the diol **10**, which was protected in the presence of benzoyl chloride in pyridine in 77% yield.

The next steps were first a selective deprotection of the *tert*-butyldiphenylsilyl ether **11** with hydrogen chloride,<sup>11</sup> a Dess–Martin oxidation<sup>12</sup> of **12**, followed by a HWE coupling reaction in the presence of dimethyl-2-oxobutylphosphonate **14**,<sup>10</sup> yielding the trans- $\alpha$ , $\beta$ -enone

ester **15** in 60% overall yield from the alcohol **12**. The relative configurations of the chiral centers were confirmed by homonuclear <sup>1</sup>H steady-state-difference NOE spectroscopy (DNOES) experiments (vide infra).

CArticle

The diastereoselective reduction of the C16 keto group in **15** with the chiral reducing agents<sup>13</sup> (*S*)- and (*R*)-BINAL-H gave the desired pure 16(*S*) derivative **16** and its 16(*R*) epimer **17** in 85% and 87% yield, respectively (Scheme 4).

Finally, saponification of ester functions, followed by treatment with an excess of  $CH_2N_2$ , afforded the desired *ent*-PPF<sub>1</sub> type I **1** and its 16 epimer **2** in 20% and 19% yields, respectively, from **3**, after 9 steps.

**Synthesis of** *ent***-Phytoprostanes F**<sub>1</sub> **Type II 31 and 32 from D-Glucose.** Since the PPF<sub>1</sub> type II diaster-


<sup>(9)</sup> Roland, A.; Durand, T.; Egron, D.; Vidal, J. P.; Rossi, J. C. J. Chem. Soc., Perkin Trans 2 2000, 245–251 and references therein. (10) Copolla, G. A. Synthesis 1988, 81–84.

<sup>(11)</sup> Nashed, E. M.; Glaudemans, C. P. J. *J. Org. Chem.* **1987**, *52*, 5255–5260.

<sup>(12)</sup> Dess, D. B.; Martin, J. C. J. Org. Chem. **1983**, 48, 4155–4156. Ireland, R. E.; Liu, L. J. Org. Chem. **1993**, 58, 2899.


<sup>(13)</sup> Noyori, R.; Tomino, I.; Tanimoto, Y.; Nishizawa, M. J. Am. Chem. Soc. **1984**, 106, 6709-6716.

## SCHEME 3. Synthesis of Precursor 15<sup>a</sup>




<sup>*a*</sup> Reagents and conditions: (a) 1.1 equiv of DIBAL-H (1 M in toluene), toluene, -80 °C, 30 min, 97%. (b) 2.25 equiv of methoxycarbonylpentyltriphenylphosphonium iodide, 2.2 equiv of KN(SiMe<sub>3</sub>)<sub>2</sub>, THF, -80 to 20 °C, 2 h, 70%. (c) H<sub>2</sub>, Pd/C 10%, EtOH, 4 h, 98%. (d) 3 equiv of BzCl, pyridine, 20 °C, 1 h, 77%. (e) HCl 3% in MeOH, 20 °C, overnight, 80%. (f) Periodinane, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 h. (g) 3.3 equiv of dimethyl 2-oxobutylphosphonate **14**, 3 equiv of NaN(SiMe<sub>3</sub>)<sub>2</sub>, THF, 20 °C, 30 min, 60%.

## SCHEME 4. Synthesis of ent-Phytoprostanes F<sub>1</sub> Type I 1 and 2<sup>a</sup>



<sup>a</sup> Reagents and conditions: (a) (*S*)-BINAL-H, -100 °C, 2 h, 85%. (b) (*R*)-BINAL-H, -100 °C, 2 h, 87%. (c) 1 N NaOH, THF–MeOH, rt, 1 h, then CH<sub>2</sub>N<sub>2</sub> 91% for 1 and 93% for 2.



<sup>*a*</sup> Reagents and conditions: (a) (i) *n*-BuLi, THF, -78 °C; (ii) diethylazelate, -78 °C, 3.5 h, 57%.

TABLE 1.  $[\alpha]^{20}_D$  (1  $\times$  10<sup>-2</sup>, MeOH) for All Diastereomers of PPF<sub>1</sub> Types I and II

diastereomer	$[\alpha]^{20}D$	$[\alpha]^{20}{}_{\rm D}$	diastereomer
<i>ent</i> -PPF <sub>1</sub> type I ( <b>1</b> )	-30	+25	PPF <sub>1</sub> type I ( <b>1</b> ′)
<i>ent</i> -16- <i>epi</i> -PPF <sub>1</sub> type I ( <b>2</b> )	-13	+14	16- <i>epi</i> -PPF <sub>1</sub> type I ( <b>2</b> ')
<i>ent</i> -PPF <sub>1</sub> Type II ( <b>31</b> )	-26	+23	PPF <sub>1</sub> type II ( <b>31</b> ′)
ent-9-epi-PPF <sub>1</sub> type II ( <b>32</b> )	-7	+7	9- <i>epi</i> -PPF <sub>1</sub> type II ( <b>32</b> ')

eomers had never previously been prepared, we have performed the synthesis of these type II  $PPF_1$  as shown in Schemes 6 and 7.


The  $\beta$ -ketophosphonate **19** was selected and prepared by using the following procedure published by Miftakhov et al.<sup>14</sup> and outlined in Scheme 5. The lithio derivative of dimethyl methylphosphonate **18** reacts with the diethylazelate to afford the corresponding  $\beta$ -ketophosphonate **19** in 57% yield.

The alkoxyester **3** was converted into the primary alcohol **20** by treatment with lithium aluminum hydride (LAH) in anhydrous ether in 94% yield (Scheme 6). The following protection, using toluenesulfonyl chloride, led to the corresponding tosylate **21** in 97% yield, which was reduced, once again, by LAH in refluxing ether to afford the methyl group of the  $\alpha$  chain in 91% yield.

The introduction of the  $\omega$  chain of the PPF<sub>1</sub> type II started by the regioselective deprotection of the bistriethylsilyloxy ether in the presence of *tert*-butyldiphenylsilyl ether, using ammonium fluoride in MeOH/THF to afford the diol **23** in 82% yield. The protection of the hydroxyl functions of **23** with benzoyl chloride in dry pyridine gave the diester **24** in 94% yield.

The *tert*-butyldiphenylsilyl ether **24** was converted into the alcohol **25** by treatment with a solution of 3% hydrogen chloride<sup>11</sup> in methanol/diethyl ether (1:1). Oxidation of the alcohol **25** with the Dess–Martin periodinane<sup>12</sup> provided the unstable aldehyde **26**, which was immediately used in the next step without purification.

The condensation of **26** with dimethyl 9-(ethoxycarbonyl)-2-oxononylphosphonate **19**,<sup>14</sup> in the presence of sodium hexamethyldisilyl amide, in anhydrous THF at room temperature, afforded the trans- $\alpha$ , $\beta$ -enone ester **27** in 79% overall yield from alcohol **25** (Scheme 7). During the HWE reaction, it was not possible to avoid the formation of compound **28** derived from the elimination of the benzoyl group at C13, as already observed in other



<sup>a</sup> Reagents and conditions: (a) 1.5 equiv of LAH (1 M in THF), diethyl ether, -78 °C, 1 h, 94%. (b) DMP, TEA, 1.5 equiv of TsCl, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 h, 97%. (c) 1.1 equiv of LAH (1 M in THF), diethyl ether, reflux, 91%. (d) 4 equiv of NH<sub>4</sub>F, MeOH/THF (7:3), reflux, 2 h, 82%. (e) 3 equiv of BzCl, pyridine, rt, 1 h, 94%. (f) HCl 3% in MeOH/Et<sub>2</sub>O (1:1), rt, overnight, 97%. (g) Periodinane, CH<sub>2</sub>Cl<sub>2</sub>, rt, 30 min. (h) 3 equiv of MaN(SiMe<sub>3</sub>)<sub>2</sub>, THF, rt, 1 h, 79%.

series. The relative configurations of the chiral centers were confirmed by homonuclear <sup>1</sup>H steady-state-difference NOE spectroscopy (DNOES) experiments (vide infra).


The diastereoselective reduction of the C9 keto group in **27** with the chiral reducing agents<sup>13</sup> (*R*)- and (*S*)-BINAL-H gave the desired pure 9(R) derivative **29** and its 9(S) epimer **30** in 82% and 89% yield, respectively (Scheme 7).

Finally, deprotection of the benzoyl groups in **29** and **30**, in the presence of 1 N NaOH at room temperature, followed by excess of  $CH_2N_2$ , afforded the desired *ent*-PPF<sub>1</sub> type II **31** and its 9 epimer **32** in 38% and 42% yields, respectively, from the cyclopentane alkoxyester **3**, in 10 steps.

Syntheses of Phytoprostanes  $F_1$  Types I and II 1', 2', 31', and 32' from L-Glucose. All reactions of Dglucose have been duplicated with L-glucose leading to


<sup>(14)</sup> Miftakhov, M. S.; Akhmetvaleev, R. R.; Imaeva, L. R.; Vostrikov, N. S.; Saitova, M. Yu.; Zarudij, F. S.; Tolstikov G. A. *Khim.-Pharm. Zurnal.* **1996**, *30* (8), 22–27.

## SCHEME 7. Syntheses of ent-Phytoprostanes F<sub>1</sub> Type II 31 and 32<sup>a</sup>



<sup>a</sup> Reagents and conditions: (a) (*S*)-BINAL-H, -100 °C, 2 h, 89%. (b) (*R*)-BINAL-H, -100 °C, 2 h, 82%. (c) 1 N NaOH, THF/MeOH, rt, 1 h, then CH<sub>2</sub>N<sub>2</sub> 96% for **31** and 94% for **32**.

## SCHEME 8. Syntheses of Phytoprostanes $F_1$ Type I and Type II 1', 2', 31', and 32'



the enantiomerically pure  $PPF_1$  types I and II diastereomers 1', 2', 31', and 32' as shown in Scheme 8.

The physicochemical properties of the enantiomerically pure  $PPF_1$  types I and II diastereomers 1', 2', 31', and 32' were identical with those of 1, 2, 31, and 32 except for the sign of specific optical rotation, as mentioned in Table 1.

**Structural Determination of**  $\alpha,\beta$ **-Enones 15, 15', 27, and 27'.** The relative configurations of chiral centers were confirmed by homonuclear <sup>1</sup>H steady-state-difference NOE spectroscopy (DNOES) experiments as shown in Figure 1.

For compound **15**, the relative cis configuration of the protons 11-H, 1-H, 4-H, and 6-H was determined by

# **JOC** Article




FIGURE 1. Observed NOEs resulting from irradiation of main protons are indicated with solid lines.

irradiation of 11-H, which induced NOEs of 1.3% on 1-H, 3.9% on 6-H, 5.2% on 4-H, and 0.7% on 7-H. Irradiation of 6-H induced NOEs of 1.0% on 1-H and 0.75% on 4-H. Similar results were observed for compound **15**′, the enantiomer of compound **15**.

Irradiation of 11-H induces a NOE of 6.3% on 6-H, 2.4% on 1-H, and 8.1% on 4-H, while irradiation of 6-H induces a NOE of 2.1% on 1-H and 1.3% on 4-H. These observations verify the relative cis configuration of the protons 1-H, 4-H, 6-H, and 11-H.

Concerning **27**, the irradiation of 6-H showed a NOE of 2.8% on 8-H, 2.1% on 4-H, and 0.88% on 1-H. Likewise, the irradiation of 8-H induces a NOE of 1.9% on 1-H and 1.3% on 4-H. These observations allow one to check the relative cis configuration of protons 1-H, 4-H, 6-H, and 8-H.

For compound **27**′, the enantiomer of compound **27**, the relative cis configuration of the protons 1-H, 4-H, 6-H, and 8-H was determined by irradiation of 6-H, which induced NOEs of 3.1% on 4-H, 1.8% on 1-H, and 2.4% on 8-H. Irradiation of 8-H induced NOEs of 3.0% on 1-H and 1.9% on 4-H.

### Conclusion

In conclusion, the first synthesis of the eight enantiomerically pure diastereomers of the syn-anti-syn phytoprostanes  $F_1$  types I and II has been accomplished starting form enantiopure alkoxyesters **3** and **3'**. Further studies of other phytoprostanes or analogues, as well as the assessment of individual biological activities in human and/or plant, are in progress and will be reported in due course.

**Acknowledgment.** We gratefully acknowledge the Ministère de l'Education Nationale et de la Recherche for financial support for one of us (S.E). The authors are grateful to Dr. A. Vidal for carefully reading the manuscript.

**Supporting Information Available:** Experimental procedures for syntheses and <sup>1</sup>H NMR and <sup>13</sup>C NMR data for compounds 5–7, 8–17, 19, 20–30, and the target compounds 1, 2, 31, 32, 1', 2', 31', and 32'. This material is available free of charge via the Internet at http://pubs.acs.org.

#### JO035638I